These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 20593908)

  • 1. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.
    Grimwood K; Lambert SB; Milne RJ
    Paediatr Drugs; 2010 Aug; 12(4):235-56. PubMed ID: 20593908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotavirus vaccines and vaccination in Latin America.
    Linhares AC; Bresee JS
    Rev Panam Salud Publica; 2000 Nov; 8(5):305-31. PubMed ID: 11190969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of a rotavirus immunization program for the United States.
    Tucker AW; Haddix AC; Bresee JS; Holman RC; Parashar UD; Glass RI
    JAMA; 1998 May; 279(17):1371-6. PubMed ID: 9582045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
    Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
    BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First rotavirus vaccine licensed: is there really a need?
    Glass RI; Bresee JS; Parashar UD; Holman RC; Gentsch JR
    Acta Paediatr Suppl; 1999 Jan; 88(426):2-8. PubMed ID: 10088904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotavirus vaccines against diarrhoeal disease.
    Vesikari T
    Lancet; 1997 Nov; 350(9090):1538-41. PubMed ID: 9388411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011.
    Lopman BA; Payne DC; Tate JE; Patel MM; Cortese MM; Parashar UD
    Curr Opin Virol; 2012 Aug; 2(4):434-42. PubMed ID: 22749491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies.
    Hungerford D; Smith K; Tucker A; Iturriza-Gómara M; Vivancos R; McLeonard C; A Cunliffe N; French N
    BMC Infect Dis; 2017 Aug; 17(1):569. PubMed ID: 28810833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
    Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL
    Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for development of a rotavirus vaccine against rotavirus diarrhea in infants and young children.
    Kapikian AZ; Flores J; Hoshino Y; Midthun K; Gorziglia M; Green KY; Chanock RM; Potash L; Sears SD; Clements ML
    Rev Infect Dis; 1989; 11 Suppl 3():S539-46. PubMed ID: 2548276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
    Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
    Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.